After the results, various brokerage companies have revised their target price for the share, with estimates that are as high as RS 1,875 per share, which indicates a further upward potential.
The Pharma Major reported a growth of 10% on an annual basis (JoJ) in the consolidated profit after tax (Pat) to RS 1.298 Crore for the quarter ending in June 2025, against RS 1,178 Crore in the same quarter last year. Pat rose by 6% of RS 1,222 Crore in Q4FY25 on a sequential basis, which underlines the ongoing winning momentum.
Cipla’s turnover from operations increased by 4% JoJ to RS 6.957 Crore, an increase in RS 6,693 Crore in the corresponding quarter of the previous year. Successively, sales increased by 3.4% of RS 6,730 crore in Q4FY25.
Profit for interest, taxes, depreciation and amortization (EBITDA) for the quarter was on RS 1,778 Crore and registered an increase of 4% JOJ. The EBITDA margin, however, witnessed a marginal decline of 7 basic points, which settled at 25.6%.
Cipla also maintained a healthy balance, with a total debt at RS 459 Crore and Kas reserves of RS 10,838 Crore on 30 June 2025. The net cash position of the company was RS 10,379 Crore.
This is what analysts said in different listed companies:
Antiques: buy | Target price: RS 1.875
Antique has maintained a ‘buy’ rating on Cipla and raised his target price to RS 1,875 of the earlier estimate of RS 1,760. The Brokerage emphasized Cipla’s strong Pat -Outformance, which attributes to the company’s differentiated product portfolio. It noted that the American pipeline of Cipla is gaining strength, especially in the inhalation therapy segment. The commercialization of Gadvair is expected in FY26, while Gsymbicort and two extra inhalation activa remain on schedule for launch in FY27. Antique has largely maintained his profit estimates for FY26 and FY27 and has rolled his appreciation to 27 times 1HFY28 estimated income, an increase in the estimated income of 27 times FY27.
Nuvama: Hold | Target price: RS 1.651
Nuvama has retained a ‘hold’ rating on Cipla, while he raised his target price to RS 1,651 of RS 1,620. The brokerage noted that a strong version helped the company to deliver a margin, despite the impact of Grevlimid. Cipla’s EBITDA margin was 25.6%, which exceeded the consensus estimates with 103 basic points and improved the gross margin to 68.8%, which reflects strong cost efficiency. Nuvama also emphasized Cipla’s growing market share of Lanreotide at 21%, with further upward potential. The recent launches of Gabraxane and Nilotinib have strengthened the company’s product portfolio. The most important inhalation and peptide products, including Gadvair and Gsymbicort, stay on schedule for launch, while Filgrastim is expected to debut in Q2FY26. Cipla focuses on $ 1 billion in the American turnover by FY27E.
Choice Broking: Add | Target price: RS 1,620
Choice Broking has assigned a target price of RS 1,620 (compared to RS 1,445 for Q4FY25) for Cipla, and the stock assessment has been upgraded to add.
Analysts believe that Cipla has a strong product pipeline, supported by breathing products in India and Peptides and Biosimilars in North America. This robust pipeline is expected to start a healthy growth that will start FY27, allowing the company to manage the impact of Revlimid loss on the North -American market. Although margins in FY26 can be under pressure as a result of increased capital expenditures and R&D investments, an improved product mix is expected to help compensate for this pressure in the long term.
There has been no major change in the Cipla management guidelines. Analysts have maintained their current estimates in introducing projections for FY28. The company is now appreciated on the basis of the average of FY27E and FY28E -EPS estimates, in which an unchanged multiple of 20x is applied to take into account the expected margin and return ratio.
Also read: Kotak Mahindra Bank Shares fall more than 6% after muted Q1 show. Do you have to sell now?
((Indemnification: Recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)
#Cipla #shares #shares #days #results #impression #Makelaars #increase #goal